Try our beta test site
IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more...

Study to Evaluate the Efficacy, Safety, Tolerability, and Pharmacokinetics of MBX-2982 Administered Daily for 4 Weeks as Monotherapy in Patients With Type 2 Diabetes

This study has been completed.
Information provided by (Responsible Party):
CymaBay Therapeutics, Inc. Identifier:
First received: December 17, 2009
Last updated: March 30, 2015
Last verified: March 2015
To define the relative efficacy, safety and tolerability profiles of oral daily MBX-2982 at three different daily doses vs. placebo and sitagliptin 100 mg when administered for up to 4 weeks in patients that are treatment-naive or taking a single anti-diabetic medication (non-TZD, non-injectable).

Condition Intervention Phase
Drug: MBX-2982
Drug: Sitagliptin
Drug: placebo
Phase 2

Study Type: Interventional
Study Design: Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double Blind (Participant, Care Provider, Investigator)
Primary Purpose: Treatment
Official Title: Phase 2, Randomized, Double-Blind, Placebo and Active-Comparator Controlled Study to Evaluate the Efficacy, Safety, Tolerability, and Pharmacokinetics of MBX-2982 Administered Daily for 4 Weeks as Monotherapy in Patients With Type 2 Diabetes

Further study details as provided by CymaBay Therapeutics, Inc.:

Primary Outcome Measures:
  • Evaluate the effect of MBX-2982 on the absolute and percent change from baseline and placebo in mean weighted average of 14-point blood glucose levels associated with a standardized breakfast and lunch [ Time Frame: 4 weeks ]

Secondary Outcome Measures:
  • Evaluate the effect of MBX-2982 on additional glycemic parameters. [ Time Frame: 4 weeks ]

Enrollment: 100
Study Start Date: December 2009
Study Completion Date: August 2010
Primary Completion Date: August 2010 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: MBX-2982 25 mg Drug: MBX-2982
tablets and capsule once daily
Experimental: MBX-2982 100 mg Drug: MBX-2982
tablets and capsule once daily
Experimental: MBX-2982 300 mg Drug: MBX-2982
tablets and capsule once daily
Active Comparator: Sitagliptin 100 mg Drug: Sitagliptin
tablets and capsule once daily
Placebo Comparator: Placebo Drug: placebo
tablets and capsule once daily

Detailed Description:
Approximately 100 patients will be randomized in this study, 20 to each of of the three MBX-2982 treatment groups, 20 to placebo, and 20 to the sitagliptin group. Patients will be taking 3 tablets and 1 capsule daily. This sample size provides the minimum number expected to ensure a power of at least 80% to detect a 20% decrease in the weighted mean glucose level associated with an extended mixed meal tolerance test (with 2 standardized meals) relative to placebo after 4 weeks of daily treatment with MBX-2982, assuming a drop-out rate of 20% and a common SD of 25%.

Ages Eligible for Study:   18 Years to 70 Years   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • History of type 2 diabetes of at least 3 months duration
  • Treatment-naïve (not on any anti-diabetic medication) or treated with a single anti-diabetic agent (excluding insulin, exenatide or other GLP-1 analogs, pioglitazone or rosiglitazone)
  • HbA1c 7.0-8.5% (inclusive) at screening
  • BMI ≥ 26 kg/m2 for patients recruited from U.S or Georgia or ≥ 22 kg/m2 for patients recruited from India

Exclusion Criteria:

  • Any history of type 1 diabetes or diabetic ketoacidosis
  • History of major upper GI surgery
  • Evidence or history of clinically significant GI illness including dyspepsia, PUD, nausea, diarrhea, malabsorption, etc.
  • History of outpatient insulin use within last 1 year (insulin use while hospitalized is acceptable)
  • Weight loss > 10 pounds (4.5 kg) in the 3 months prior to screening visit or use of weight loss medications (prescription or OTC) within 30 days of screening
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT01035879

United States, California
Impact Clinical Trials
Los Angeles, California, United States, 90036
United States, Nevada
Nevada Alliance Against Diabetes
Las Vegas, Nevada, United States, 89101
United States, New York
United Medical Associates
Binghamton, New York, United States, 13901
United States, Texas
dgd Research, Inc., a Cetero Research Co.
San Antonio, Texas, United States, 78229
Healthy Life Clinical Diagnostic Center
Tbilisi, Georgia, 0144
Georgian Diabetes Center
Tbilisi, Georgia, 0159
Medulla Chemotherapy and Immunotherapy Clinic
Tbilisi, Georgia, 0186
Bharti Research Institute of Diabetes and Endocrinology
Karnal, Haryana, India, 132001
Diabetes Thyroid Hormone Research Institute Pvt Ltd
Indore, M.p., India, 452001
Gandhi Endocrinology & Diabetes Centre
Ramdaspeth, Nagpur, India, 10
Gokula Metropolis Research, MS Ramaiah Memorial Hospital
Bangalore, India, 560 054
Medisys Clinisearch India Pvt Ltd
Bangalore, India, 560043
Hormone Care Research Centre
Ghaziabad, India, 201002
Bangalore Endocrinology & Diabetes Research Centre
Malleshwaram, India, 560 003
Sponsors and Collaborators
CymaBay Therapeutics, Inc.
Study Director: Brian Roberts, MD Metabolex, Inc.
  More Information

Responsible Party: CymaBay Therapeutics, Inc. Identifier: NCT01035879     History of Changes
Other Study ID Numbers: M2982-20920
Study First Received: December 17, 2009
Last Updated: March 30, 2015

Additional relevant MeSH terms:
Diabetes Mellitus
Glucose Metabolism Disorders
Metabolic Diseases
Endocrine System Diseases
Sitagliptin Phosphate
Hypoglycemic Agents
Physiological Effects of Drugs
Hormones, Hormone Substitutes, and Hormone Antagonists
Dipeptidyl-Peptidase IV Inhibitors
Protease Inhibitors
Enzyme Inhibitors
Molecular Mechanisms of Pharmacological Action processed this record on May 25, 2017